Bristol Myers Squibb, Bain Capital Create Company Focused on Developing Immunology Therapies

Bristol Myers Squibb, Bain Capital create company focused on developing immunology therapies

Bristol Myers Squibb and Bain Capital announced the creation of an independent biopharmaceutical company focused on developing therapies for autoimmune diseases that address unmet needs of patients. The new company launches with five immunology assets in-licensed from BMS and a $300 million financing commitment led by Bain Capital. The NewCo has a pipeline consisting of three clinical-stage and two Phase 1-ready investigational medicines that ea…

Bain Capital, Bristol Myers Squibb launch $300m immunology venture - Private Equity Wire

Bain Capital has joined forces with Bristol Myers Squibb to establish an independent biopharmaceutical company focused on immunology, backed by a $300m financing round led by the private equity firm, according to a report by Reuters. The new entity will develop a portfolio of five clinical-stage immunology assets exclusively licensed from Bristol Myers Squibb. The pipeline includes a late-stage candidate for lupus and a mid-stage psoriasis thera…